Who
David Scott Moore
Director
Company insider
Files Form 4 as: Director, Corvus Pharmaceuticals.
In numbers
- Trades disclosed
- 5
- Buys
- 1
- Sells
- 0
- Bought
- $500K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 2 Oct 2025
- Last trade
- 11 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Jun – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 15 Jun 2026 | CRVS Corvus PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $250K21,700 at $11.53 | filing |
| 11 Jun 2026filed 15 Jun 2026 | CRVS Corvus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | CRVS Corvus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | CRVS Corvus PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $250K21,700 at $11.53 | filing |
| 2 Oct 2025filed 6 Oct 2025 | CRVS Corvus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.